NAD+ and Longevity: Why Your Cells Run Out of Fuel as You Age — And What the Evidence Says About Restoring It

By Dr. Tom Biernacki, DPM | Balance Foot & Ankle | Howell & Bloomfield Hills, Michigan

In This Article

• What Is NAD+ and Why It Matters for Every Cell
• The NAD+ Decline of Aging: Timeline, Causes, and Consequences
• Sirtuins: The Longevity Proteins That Need NAD+ to Function
• PARP1 and DNA Repair: How NAD+ Depletion Lets Mutations Accumulate
• How to Raise NAD+: Evidence-Based Strategies
• The Practical Supplement Question: NMN vs NR vs Niacin
• The Clinical Connection: NAD+ and Peripheral Nerve Health
• Frequently Asked Questions
• Sources

In 2013, David Sinclair’s laboratory at Harvard published a paper in Cell that generated more popular coverage of longevity science than almost anything published in the preceding decade. The research demonstrated that raising NAD+ levels in aged mice using an NAD+ precursor reversed several hallmarks of muscle aging within just one week — restoring the vascular function, mitochondrial density, and endurance capacity of old mice to levels resembling much younger animals. The finding was extraordinary not just for what it showed, but for the implication embedded in it: aging may not simply be the inevitable accumulation of damage, but in part a reversible energy deficit at the cellular level — a molecular fuel shortage that could theoretically be corrected.

The decade since that paper has produced an explosion of NAD+ research, human clinical trials, and an enormous commercial supplement market — along with the necessary scientific caution about translating mouse longevity findings to human beings. What follows is my honest clinical assessment of the NAD+ field: what is mechanistically established, what the human evidence actually shows, and what represents reasonable evidence-based action versus premature extrapolation from animal studies.

What Is NAD+ and Why It Matters for Every Cell in Your Body

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It exists in two forms — the oxidized form (NAD+) and the reduced form (NADH) — and cycling between these two forms is literally how cells transfer energy from food to the biochemical work of staying alive. Every macronutrient you eat — carbohydrates, fats, and proteins — must ultimately be oxidized through pathways (glycolysis, the citric acid cycle, beta-oxidation) that use NAD+ as the electron acceptor. When food is broken down in the mitochondria, the electrons stripped from these molecules are transferred to NAD+, converting it to NADH. That NADH then donates its electrons to the electron transport chain, driving ATP synthesis — the universal cellular energy currency. Without adequate NAD+, cellular respiration cannot proceed. Mitochondria fail. Energy production collapses. This is not a minor biochemical footnote — it is the foundation of every cell’s ability to function.

NAD+ as Signaling Molecule: Sirtuins, PARP, and CD38

Beyond its role as a metabolic electron carrier, NAD+ is a critical substrate — meaning it is consumed, not just cycled — in three major signaling systems with direct relevance to aging. The first is the sirtuin family of deacylase enzymes (SIRT1–7), which use NAD+ to remove acetyl groups from histones and other proteins, regulating gene expression, mitochondrial biogenesis, DNA repair, inflammation, and stress resistance. Sirtuins are often called “longevity proteins” because activating them extends lifespan in multiple model organisms — but critically, they require adequate NAD+ to function. A sirtuin without NAD+ is like an enzyme without its cofactor: biologically inert.

The second major NAD+-consuming signaling system is PARP (poly ADP-ribose polymerase), specifically PARP1. When DNA is damaged — by reactive oxygen species, radiation, chemical mutagens, or replication errors — PARP1 rapidly consumes NAD+ to build poly-ADP-ribose chains at the damage site, which serve as a scaffold for recruiting DNA repair machinery. PARP1 is one of the most voracious NAD+ consumers in the cell; a single strand of DNA damage can activate PARP1 to consume hundreds of NAD+ molecules in seconds. As DNA damage accumulates with aging — and accumulates faster in metabolically stressed, chronically inflamed tissue — PARP1 activity increases dramatically, competing with sirtuins for the diminishing NAD+ pool. This competition is one mechanism through which the hallmarks of aging (DNA damage and epigenetic dysregulation) mutually amplify each other.

The third major NAD+ consumer in aging tissue is CD38, an NAD+-glycohydrolase enzyme expressed on immune cells and upregulated markedly during inflammation and aging. CD38 does not recycle NAD+ — it destroys it, producing cyclic ADP-ribose (cADPR) as a calcium signaling molecule. In aged tissues with chronic low-grade inflammation (inflammaging), CD38 expression increases substantially, creating a chronic drain on the cellular NAD+ pool that compounds the metabolic and signaling deficits. Knockout of CD38 in mice significantly preserves NAD+ levels in aged tissue — establishing CD38 as a primary driver of age-related NAD+ decline, and identifying CD38 inhibition as a potential therapeutic target alongside NAD+ precursor supplementation.

The NAD+ Decline of Aging: Timeline, Causes, and Consequences

NAD+ levels in human tissue decline measurably and consistently with aging. Studies measuring NAD+ in human skeletal muscle, skin, blood mononuclear cells, and tissue biopsies consistently show approximately 50% lower NAD+ concentrations in individuals in their 50s–60s compared to those in their 20s–30s. This is not a subtle statistical trend — it is a major quantitative shift in a molecule that is required for hundreds of biological reactions. The consequences manifest across multiple organ systems simultaneously, which is one reason aging presents as a diffuse decline rather than a single system failure.

Why NAD+ Falls So Dramatically: The CD38-Inflammation Spiral

The primary drivers of age-related NAD+ decline are now reasonably well understood. Biosynthetic capacity for NAD+ — particularly through the salvage pathway, which recycles nicotinamide back into NAD+ via NAMPT (the rate-limiting enzyme in NAD+ biosynthesis) — declines in aged tissue. NAMPT expression and activity decrease in multiple tissue types with aging, reducing the cell’s ability to replenish consumed NAD+. Simultaneously, consumption dramatically increases: accumulated DNA damage drives sustained PARP1 activation; inflammaging-driven CD38 upregulation creates chronic enzymatic destruction of NAD+; and the telomere shortening and mitochondrial dysfunction that characterize aging independently stimulate additional DNA damage repair activity, further depleting the pool.

The result is a classic demand-exceeds-supply spiral. NAD+ biosynthesis slows while consumption accelerates, creating a widening deficit that impairs every NAD+-dependent function simultaneously: mitochondrial energy production falters, sirtuins lose their NAD+ substrate and become inactive, DNA repair becomes substrate-limited, and circadian rhythm maintenance (which requires NAD+/SIRT1 signaling through NAMPT-PER2 feedback loops) begins to fragment. The circadian disruption in turn worsens metabolic dysfunction, which increases reactive oxygen species, which increases DNA damage, which increases PARP1 activity, which depletes more NAD+. This is the biochemical architecture of the aging spiral.

Consequences of NAD+ Decline: The Hallmarks Connection

López-Otín and colleagues’ landmark 2013 Cell paper (updated in 2023) catalogued 12 hallmarks of aging — the molecular and cellular changes that collectively constitute biological aging. NAD+ decline connects to at least seven of these hallmarks directly. Mitochondrial dysfunction (hallmark 5): NAD+ depletion impairs the electron transport chain, reducing ATP production and increasing mitochondrial ROS generation. Epigenetic alterations (hallmark 2): SIRT1 and SIRT6 inactivation from NAD+ depletion disrupts histone deacetylation patterns and DNA methylation maintenance. Genomic instability (hallmark 1): PARP1 substrate limitation impairs double-strand and single-strand DNA break repair. Loss of proteostasis (hallmark 4): NAD+-dependent SIRT1 activates autophagy and proteasome function — both impaired by NAD+ deficiency. Cellular senescence (hallmark 7): NAD+-depleted cells accumulate DNA damage faster, reaching the senescence threshold sooner. Stem cell exhaustion (hallmark 11): Tissue stem cell populations in NAD+-deficient aged animals show markedly impaired self-renewal capacity, reversible with NAD+ precursor treatment. Altered intercellular communication (hallmark 10): SIRT1 suppresses NF-κB and inflammatory cytokine production — NAD+ depletion releases this brake, promoting inflammaging.

Sirtuins: The Longevity Proteins That Need NAD+ to Function

The sirtuin family consists of seven proteins (SIRT1–SIRT7) distributed across different cellular compartments — nucleus (SIRT1, SIRT2, SIRT6, SIRT7), mitochondria (SIRT3, SIRT4, SIRT5), and cytoplasm (SIRT2). Each has distinct substrates and functions, but all share the critical feature of requiring NAD+ as a cosubstrate for their enzymatic activity — not as a carrier that gets recycled, but as a molecule that is consumed in the reaction, yielding nicotinamide as a byproduct. This means that sirtuin activity is directly gated by cellular NAD+ availability: when NAD+ is abundant (fasting, exercise, youth), sirtuins are active; when NAD+ is depleted (aging, chronic disease, sedentary lifestyle), sirtuins fall silent regardless of whether the proteins themselves are present.

SIRT1: The Master Metabolic and Epigenetic Regulator

SIRT1 is the most extensively studied sirtuin and the one most directly implicated in longevity pathways. Its substrates include histones H3 and H4 (regulating which genes are expressed), PGC-1α (the master regulator of mitochondrial biogenesis — SIRT1 activation drives cells to generate more, healthier mitochondria), FOXO transcription factors (stress resistance and longevity genes), p53 (cell death and senescence regulation), and NF-κB (inflammatory gene expression — SIRT1 suppresses it). When Sinclair’s group identified that caloric restriction extends lifespan in yeast partly through Sir2 (the sirtuin homolog) activation, and that this activation required NAD+, it established the NAD+-sirtuin-longevity axis as a mechanistic link between dietary restriction and biological aging rate.

In human terms, SIRT1 activity is the molecular explanation for why fasting, exercise, and caloric restriction produce overlapping longevity benefits: all three elevate cellular NAD+ levels, all three activate SIRT1, and SIRT1 activation drives the downstream programs — mitochondrial biogenesis, anti-inflammatory signaling, autophagy induction, stress resistance gene expression — that these interventions are known to produce. SIRT1 is not the only mediator, but it is one of the most important nodes through which NAD+ availability translates into functional longevity biology.

SIRT3: Mitochondrial Health and Energy Metabolism

SIRT3 is the primary mitochondrial sirtuin, responsible for deacetylating and activating key enzymes in oxidative phosphorylation, the citric acid cycle, and the mitochondrial antioxidant system. Its most important substrates include Complex I of the electron transport chain (SIRT3 activation improves electron transport efficiency and reduces reactive oxygen species leakage), manganese superoxide dismutase (MnSOD — the primary mitochondrial antioxidant enzyme, activated by SIRT3-mediated deacetylation), and isocitrate dehydrogenase (a key citric acid cycle enzyme). In aged tissue where SIRT3 is less active due to NAD+ depletion, these enzymes accumulate in their hyperacetylated, less active forms — contributing directly to the mitochondrial dysfunction and increased oxidative stress that characterize aged cells. SIRT3 knockout mice develop characteristics of metabolic syndrome and cancer at higher rates; overexpression protects against several age-related diseases in animal models.

SIRT6: Genome Stability and the Epigenetic Aging Clock

SIRT6 has emerged as perhaps the most directly relevant sirtuin to the hallmarks of aging. Its primary functions are maintaining genome stability (SIRT6 recruits DNA repair factors to double-strand breaks and repairs telomeric DNA — SIRT6 knockout mice develop severe genomic instability and die prematurely from a syndrome resembling accelerated aging) and epigenetic maintenance (SIRT6 deacetylates H3K9 and H3K56 at gene promoters, maintaining the repressive chromatin state that keeps transposable elements, oncogenes, and inflammatory genes silenced). When Vera Gorbunova’s laboratory overexpressed SIRT6 in male mice in 2012, they lived approximately 15% longer than controls — one of the largest lifespan extensions ever achieved through overexpression of a single gene in mammals.

In the context of NAD+ aging, SIRT6 activity falls substantially in aged tissue, contributing to the progressive loss of epigenetic landscape fidelity that Steve Horvath’s DNA methylation aging clocks can quantify. The DNA methylation clock essentially measures the accumulated epigenetic “drift” from chromatin maintenance failures — and SIRT6 insufficiency, driven by NAD+ depletion, is one of the primary maintenance failures it is measuring. This is the mechanistic foundation for David Sinclair’s information theory of aging: aging is the loss of epigenetic information, and restoring NAD+/sirtuin function is one strategy to slow or reverse that information loss.

PARP1 and DNA Repair: How NAD+ Depletion Lets Mutations Accumulate

Every cell in the human body sustains approximately 10,000–100,000 DNA damage events per day — the result of normal metabolic processes (reactive oxygen species from mitochondrial respiration), exogenous exposures (UV radiation, environmental mutagens), and replication errors during cell division. The vast majority of this damage is repaired within minutes by a sophisticated multi-pathway DNA repair machinery. PARP1 is the first responder to the most common type of damage: single-strand DNA breaks. It detects breaks within seconds of occurrence and immediately begins consuming NAD+ to build poly-ADP-ribose scaffolds that recruit repair factors.

The NAD+-PARP1-DNA repair system creates a critical vulnerability as NAD+ declines with aging. In young cells with abundant NAD+, PARP1 can repair each damage event rapidly and completely before it propagates. As NAD+ falls in aging cells, PARP1 activity becomes substrate-limited — there is simply not enough NAD+ to fuel the repair of the increasing DNA damage load that older, more metabolically stressed cells accumulate. Incompletely repaired DNA damage persists longer, creating greater opportunities for replication errors, chromosomal instability, and the integration of harmful transposable elements. This is the direct mechanistic link between NAD+ depletion and the genomic instability hallmark of aging: the cellular repair budget has been cut while the damage workload has increased.

The competition between PARP1 and sirtuins for the diminishing NAD+ pool creates an additional vicious cycle. When NAD+ is depleted by PARP1 activation, SIRT1 activity falls — impairing the SIRT1-mediated activation of DNA damage response proteins (NBS1, Ku70, Werner helicase) that PARP1 depends on for efficient repair. Less NAD+ means less SIRT1 activity means worse DNA repair efficiency means more DNA damage means more PARP1 activation means even less NAD+. This feedback loop is one of the core mechanisms through which aging accelerates in older tissue rather than progressing linearly.

How to Raise NAD+: Evidence-Based Strategies

Before discussing specific NAD+ precursor supplements, I want to emphasize that the two most potent, consistently evidence-supported NAD+ boosting strategies do not require a single capsule. Exercise and fasting elevate cellular NAD+ through multiple mechanisms and have the additional advantage of decades of human outcome data confirming their actual longevity benefits — data that NAD+ supplements, despite strong mechanistic plausibility, do not yet possess at comparable scale or duration. I begin here deliberately because the supplement industry’s enthusiasm for NMN and NR tends to overshadow the free interventions that work at least as well in the short term and far better in the long term.

Exercise: The Most Potent Natural NAD+ Booster

Exercise elevates NAD+ levels in exercising muscle through several converging mechanisms. During aerobic and resistance exercise, muscle cells experience massive increases in energy demand, dramatically accelerating the cycling of NAD+ to NADH and back (the fundamental metabolic flux that drives ATP production). This increased NAD+/NADH cycling activates AMPK, which in turn phosphorylates and activates NAMPT — the rate-limiting enzyme in NAD+ biosynthesis — increasing the rate of NAD+ production. Exercise also induces mitochondrial biogenesis through SIRT1/PGC-1α activation, expanding the mitochondrial pool that uses and recycles NAD+, and reduces CD38 activity in exercised tissue (partly through reduced tissue inflammation). A 2020 study by Canto and colleagues established that a single bout of aerobic exercise significantly elevated skeletal muscle NAD+ levels in both young and older adults, with the effect measurable within 30 minutes of exercise onset.

The exercise-NAD+ relationship also provides important context for interpreting NMN/NR supplement data. When NAD+ supplementation studies show significant improvements in muscle NAD+ levels, they are often achieving levels comparable to what regular exercise produces naturally — without the cardiovascular adaptation, mitochondrial quality improvement, BDNF elevation, skeletal mass preservation, and longevity biomarker improvements that exercise simultaneously provides. The theoretical advantage of supplementation is systemic NAD+ elevation in tissues that exercise less directly — particularly the brain, liver, and immune cells — and the ability to achieve supraphysiological NAD+ levels in aged tissue that may no longer respond fully to exercise-induced NAMPT activation.

Fasting and Caloric Restriction: NAD+ Through Metabolic Shift

Caloric restriction and intermittent fasting raise NAD+ levels through a distinct but complementary mechanism: by reducing dietary glucose and insulin signaling, they relieve the PARP1 and CD38 activation burden driven by post-meal reactive oxygen species production and chronic insulin-signaling-induced metabolic stress. Additionally, fasting activates AMPK (through declining cellular energy status) and SIRT1 in a mutually reinforcing loop: AMPK activation increases NAMPT expression, raising NAD+, which activates SIRT1, which activates AMPK — creating a feed-forward activation of the longevity pathway. The fact that caloric restriction extends lifespan in virtually every model organism tested is partly attributable to this NAD+/sirtuin pathway activation.

A 2019 study by Yoshino and colleagues measured skeletal muscle NAD+ in obese postmenopausal women randomized to caloric restriction plus exercise versus neither intervention over 12 weeks. The lifestyle intervention group showed significantly higher skeletal muscle NAD+ levels at endpoint, with NAD+ increases correlating with improvements in insulin sensitivity, oxidative capacity, and gene expression signatures consistent with sirtuin activation. Critically, the NAD+ increase was achievable through lifestyle intervention alone, without any supplement — reinforcing the foundational clinical message that behavioral interventions are the evidence-established platform on which any supplementation should be layered, not replaced.

The Practical Supplement Question: NMN vs NR vs Niacin

The commercial NAD+ precursor market has grown to billions of dollars globally, dominated by two main molecules: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). A third option — niacin (nicotinic acid) or nicotinamide — is older, far less expensive, and metabolically distinct in important ways. Evaluating these options requires separating the mechanistic evidence (does the supplement raise blood/tissue NAD+?) from the outcomes evidence (does raising NAD+ this way improve health outcomes in humans?). The first question has reasonably good human data; the second is still emerging.

NMN: The David Sinclair Molecule and Its Human Trial Data

NMN is a direct precursor in the NAD+ salvage pathway — it sits one step upstream of NAD+ itself. The 2013 Sinclair paper used NMN to raise NAD+ in aged mice; the subsequent decade of mouse longevity work has been primarily conducted with NMN. In humans, the pivotal pharmacokinetic study was a 2020 paper by Irie and colleagues in Japan demonstrating that a single oral dose of 100, 250, or 500 mg NMN was safe, dose-dependently absorbed, and produced measurable increases in blood NAD+ metabolites within 2–3 hours — establishing for the first time that oral NMN could successfully raise human NAD+ levels.

The most comprehensive human NMN RCT to date was published in 2021 in Cell Reports Medicine by Yoshino and colleagues. Overweight or obese postmenopausal women received 250 mg NMN daily or placebo for 10 weeks. The NMN group showed significant increases in skeletal muscle NAD+ (measured by tissue biopsy), increased expression of NAD+-dependent genes consistent with sirtuin activation, and improved insulin signaling in skeletal muscle — without changes in body composition, cardiovascular risk markers, or other systemic endpoints. This study provides genuine human mechanistic evidence that NMN reaches skeletal muscle and activates longevity pathways there. It does not provide evidence that these changes translate to reduced aging rates or extended healthy lifespan in humans.

Higher doses of NMN have been examined in a 2023 study of older adults (65+) receiving 300 mg or 900 mg NMN daily for 60 days. Both doses significantly increased blood NAD+ metabolites, with no serious adverse events. Subjective improvements in physical function scores were reported at 900 mg, though the study was not powered to draw definitive conclusions. A separate Japanese study found that 250 mg NMN daily for 12 weeks improved muscle endurance (grip strength, walking pace) in older men compared to placebo — an important functional endpoint that goes beyond biomarker elevation. The current evidence positions NMN as a safe, bioavailable NAD+ precursor in humans with mechanistic activity in target tissues, with emerging functional benefits in older populations.

NR: The Earlier, Better-Studied Supplement

NR (nicotinamide riboside) was the first NAD+ precursor to demonstrate oral bioavailability in humans, in a landmark 2016 paper by Trammell and colleagues showing that 100, 300, and 1000 mg doses of NR dose-dependently elevated blood NAD+ metabolites over 24 hours. NR enters the cell and is converted to NMN by NRK1/NRK2 kinases, then to NAD+ — one additional enzymatic step compared to NMN’s more direct conversion. NR has accumulated a larger body of published human RCTs than NMN (partly because it was commercially available earlier), covering populations including overweight adults, older adults, patients with heart failure, COVID-19 patients with acute kidney injury, and women with BRCA mutations.

The consistent finding across NR trials is reliable blood NAD+ elevation at doses of 500–2000 mg daily, with good safety profiles and no serious adverse events reported in trials up to 12 weeks. Functional outcomes in NR trials have been more mixed. A 2018 study found no significant improvement in cardiovascular or metabolic endpoints in healthy middle-aged adults at 1000 mg NR daily for 6 weeks despite confirmed NAD+ elevation. A 2019 study found reduced blood pressure (systolic −3.9 mmHg) in older adults with mild hypertension at 500 mg NR daily for 6 weeks. The pattern across multiple NR trials suggests that NAD+ elevation does not automatically translate to uniform systemic benefits — it may depend on baseline NAD+ status, the specific tissue type, age, and concurrent lifestyle factors.

Niacin and Nicotinamide: The Older Options and Their Trade-Offs

Niacin (nicotinic acid) and nicotinamide (the amide form) are the original vitamin B3 compounds that enter NAD+ biosynthesis through the Preiss-Handler pathway (niacin) or the salvage pathway (nicotinamide). Both are substantially less expensive than NMN or NR — niacin is available for pennies per dose versus several dollars per dose for NMN/NR. Niacin effectively raises blood NAD+ and has extensive safety data from its decades of use as an anti-dyslipidemic agent (at doses of 1–2g daily, niacin meaningfully raises HDL). Its limitations for NAD+ optimization: niacin causes the well-known “flush” reaction (prostaglandin-mediated cutaneous vasodilation), which while harmless is uncomfortable enough to limit adherence at therapeutic doses; and at high doses, nicotinamide (but not niacin) inhibits sirtuin activity by acting as a product inhibitor of the sirtuin reaction — potentially counteracting the sirtuin activation that is the goal of NAD+ elevation.

My current clinical recommendation for patients asking about NAD+ supplementation: establish the behavioral foundations first — consistent aerobic exercise, intermittent fasting or caloric restraint, and 7–9 hours of quality sleep. These reliably elevate NAD+ while simultaneously providing cardiovascular, neurological, metabolic, and longevity benefits that supplements alone cannot replicate. If these are in place and the patient is motivated to add supplementation, NMN at 300–600 mg daily or NR at 500–1000 mg daily represent reasonable adjunctive options with acceptable safety profiles and emerging evidence of biological activity. They are not transformative in the absence of the behavioral platform, but they may provide meaningful synergistic benefit when layered on top of it.

The Clinical Connection: NAD+, Peripheral Nerves, and Foot Health

The relevance of NAD+ biology to podiatric medicine is more direct than it might initially appear. Peripheral nerves — the longest axons in the body, extending from the lumbar spinal cord to the tips of the toes in some cases — are among the most metabolically demanding cells in the body. Maintaining axonal integrity across a meter or more of continuous cellular structure requires extraordinary mitochondrial function, continuous cytoskeletal transport, constant repair of oxidative damage to myelin lipids, and robust DNA repair in the Schwann cells that ensheath the axons. All of these processes are fundamentally NAD+-dependent.

Peripheral neuropathy — which affects approximately 20 million Americans and is the leading cause of falls, amputations, and treatment-resistant foot pain in older adults — has a strong metabolic component that is directly upstream of NAD+ biology. Hyperglycemia-driven oxidative stress, which is the primary mechanism in diabetic peripheral neuropathy, produces exactly the conditions that deplete NAD+: massive PARP1 activation from glucose-induced DNA damage in peripheral nerve Schwann cells and dorsal root ganglion neurons, CD38 upregulation from chronic inflammation in the nerve microenvironment, and mitochondrial dysfunction in peripheral nerve axons that further compounds oxidative stress and NAD+ consumption.

Animal model research has established that NAD+ restoration — through NMN administration, NAMPT overexpression, or CD38 inhibition — significantly reduces peripheral nerve vulnerability to metabolic injury and promotes axonal regeneration after damage. A 2021 study in diabetic mouse models demonstrated that NMN supplementation prevented the development of peripheral neuropathy markers (reduced nerve conduction velocity, intraepidermal nerve fiber density loss) when administered alongside high-fat diet feeding — suggesting a potential neuroprotective role for NAD+ precursors in metabolic neuropathy. Human trial data for NAD+ supplementation in peripheral neuropathy prevention or treatment does not yet exist at adequate scale, but the mechanistic rationale is compelling and the safety profile is established.

For my patients with early diabetic peripheral neuropathy or idiopathic peripheral neuropathy who are already implementing the behavioral longevity protocol (exercise, sleep, metabolic optimization), the addition of NMN or NR supplementation is a reasonable adjunctive intervention I now discuss proactively. It is not a replacement for glycemic control, regular foot examinations, protective footwear, and mechanical offloading — the evidence-based standards of diabetic foot care. But as part of a comprehensive metabolic approach to preserving the peripheral nerves that determine whether a patient maintains sensation, balance, and walking independence into old age, addressing NAD+ biology is a logical component of the care plan.

Wound healing represents a second important clinical connection. NAD+-dependent SIRT1 activity promotes the key cellular processes in wound repair: fibroblast migration and proliferation, keratinocyte differentiation and re-epithelialization, angiogenesis through VEGF and eNOS regulation, and macrophage polarization from pro-inflammatory M1 to pro-healing M2 phenotype. Aged tissue with depleted NAD+ and reduced sirtuin activity produces exactly the impaired wound healing environment I see clinically in older patients with diabetic foot ulcers, venous stasis ulcers, and post-surgical healing complications. Whether NAD+ precursor supplementation materially improves wound healing outcomes in older or diabetic humans awaits formal RCT confirmation — but the biology says the intervention is worth pursuing as part of a comprehensive metabolic optimization approach.

Frequently Asked Questions About NAD+ and Longevity

Does taking NMN actually work in humans?

The honest answer in 2025: NMN reliably raises blood and skeletal muscle NAD+ levels in humans, and activates gene expression programs consistent with sirtuin pathway engagement. The 2021 Yoshino Cell Reports Medicine study (tissue biopsy-confirmed muscle NAD+ elevation, sirtuin target gene activation, improved insulin signaling in muscle) and the 2023 muscle function study in older adults (improved grip strength, walking pace at 250 mg daily) provide genuine human evidence of biological activity beyond just blood biomarker changes. What NMN has not yet demonstrated in humans is extended lifespan, reduced age-related disease incidence, or improved all-cause mortality — the outcome measures that ultimately matter most. The mechanistic evidence is strong; the outcomes evidence is preliminary. Taking NMN is a reasonable bet for an individual who already has the behavioral foundations in place and wants to support their NAD+-dependent biology; it is not a validated longevity intervention in the same category as exercise or caloric restraint.

What is the best time of day to take NMN or NR?

The limited human pharmacokinetic data suggests NAD+ precursor absorption is adequate regardless of meal timing. However, there are theoretical reasons to prefer morning dosing: NAD+ plays a central role in circadian clock maintenance through NAMPT-SIRT1-BMAL1 feedback loops, and NAMPT expression is itself circadian — peaking in the morning in many tissues. Taking NAD+ precursors in the morning may align supplementation with the tissue’s natural NAD+ biosynthesis peak, potentially maximizing the circadian-clock-resetting effect. Some researchers also recommend taking NMN/NR before exercise, on the theoretical basis that exercise-induced AMPK activation would synergistically amplify the NAD+-sirtuin axis activation initiated by the supplement. These are mechanistically reasonable hypotheses rather than RCT-confirmed dosing protocols, but they inform the most evidence-aligned approach currently available.

Is NAD+ the same as NADH? Which supplement should I take?

NAD+ and NADH are the oxidized and reduced forms of the same coenzyme — NAD+ receives electrons (becoming NADH) and NADH donates electrons (reverting to NAD+) in the metabolic electron transfer reactions that drive ATP production. For longevity purposes, the relevant pool is NAD+ — the oxidized form that sirtuins and PARP1 use as a substrate and that declines with aging. NADH supplements (sometimes marketed as “reduced NAD”) are not equivalent to NAD+ precursors for longevity purposes: while NADH provides reducing equivalents for energy metabolism, it does not directly address the sirtuin-substrate and PARP1-substrate deficits that drive aging pathways. If you want to support sirtuin and DNA repair activity, you want to raise NAD+ — which means taking NMN, NR, or niacin (all of which feed the biosynthetic pathways that produce NAD+), not NADH directly.

Can you take too much NMN? What are the side effects?

Published human RCTs up to 1800 mg NMN daily for 12 weeks have not identified serious adverse events. The most commonly reported minor effects are mild gastrointestinal discomfort at doses above 500 mg (nausea, loose stools), typically resolving within a week of consistent dosing or with dose reduction. One theoretical concern is that very high NAD+ elevation through supplementation — pushing sirtuin activity supraphysiologically — might have unintended consequences in certain contexts (such as in cancer cells that also benefit from activated DNA repair), though no cancer risk signal has emerged in human NAD+ supplementation trials to date. A 2023 review by Dellinger and colleagues suggested a cautious approach for patients with active malignancies until more data are available. For healthy adults seeking longevity optimization, the current evidence supports doses of 250–600 mg NMN daily as reasonable with acceptable safety — with the understanding that long-term (5+ year) safety data at sustained higher doses simply does not yet exist.

Does resveratrol work? What is its relationship to NAD+ and sirtuins?

Resveratrol — the polyphenol from red wine made famous by Sinclair’s early sirtuin research — has had a complicated relationship with the evidence over the past two decades. Sinclair’s 2003 Nature paper showed that resveratrol activated Sir2 (the yeast SIRT1 homolog) and extended yeast lifespan; subsequent mouse studies showed metabolic benefits in obese mice. However, in 2012–2013, GlaxoSmithKline (which had acquired the resveratrol-focused biotech Sirtris for $720 million) discontinued multiple resveratrol derivative drug programs after clinical trials showed inconsistent results, and independent biochemists argued that resveratrol’s in vitro SIRT1 activation was an assay artifact dependent on the specific fluorescent substrate used. The consensus currently is that resveratrol may have genuine but modest biological effects in vivo — primarily through indirect SIRT1 activation via AMPK and through its antioxidant and anti-inflammatory properties — rather than through direct allosteric SIRT1 activation. As an add-on to NMN supplementation (the combination Sinclair himself advocates publicly), resveratrol’s AMPK-activating properties may provide synergistic NAD+/sirtuin axis support. As a standalone longevity intervention, the evidence is considerably weaker than for NMN/NR or behavioral approaches.

Sources

1. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
2. Trammell SAJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nature Communications. 2016;7:12948.
3. Irie J, et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal. 2020;67(2):153-160.
4. Gomes AP, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638.
5. Kanfi Y, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012;483(7388):218-221.
6. Yoshino J, et al. NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism. 2018;27(3):513-528.

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• Cold Therapy & Brown Fat for Longevity
• Mediterranean Diet & Longevity
• Cortisol, Chronic Stress & Longevity
• Intermittent Fasting & Longevity